Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 497-505

  Lundberg, Urban ^a   Senn, Beatrice M ^a   Schuler, Wolfgang ^a   Meinke, Andreas ^a   Hanner, Markus ^a  

^a INTERCELL AG   (Austria)

Author keywords

Active immunization; ANTIGENome; Klebsiella pneumoniae; Nosocomial infections; Protection; Vaccine candidates

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL VACCINE; RECOMBINANT PROTEIN; BACTERIUM ANTIBODY; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIUM CULTURE; BLOOD SAMPLING; CELL SELECTION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENETIC CONSERVATION; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN ANALYSIS; SEPSIS; SEROTYPE; VALIDATION PROCESS; ANIMAL; BACTEREMIA; BLOOD; DISEASE MODEL; IMMUNOLOGY; KLEBSIELLA INFECTIONS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; VACCINES, SUBUNIT;

EID: 84874729270     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23225     Document Type: Conference Paper

References (45)

1. Stamm WE, Weinstein RA, Mannheim W. Comparison of endemic and epidemic nosocomial infection. Nosocomial infection. In: Dixon R E, ed. Nosocomial infections. Atlanta, Ga: Yorke Medical Books; 1981:9-13.
2. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. Lancet 2005; 365:1175-88; PMID:15794973; http://dx.doi.org/10.1016/S0140-6736(05)71881-X. (Pubitemid 40417568)
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17; PMID:15306996; http://dx.doi.org/10.1086/421946. (Pubitemid 39050477)
4. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998; 11:589-603; PMID:9767057. (Pubitemid 28497563)
5. Wu LT, Hung SW, Chuang YC, Chen HE, Jones RN, Yu WL. Identification of a novel cephalosporinase (DHA-3) in Klebsiella pneumoniae isolated in Taiwan. Clin Microbiol Infect 2005; 11:893-7; PMID:16216104; http://dx.doi.org/10.1111/j. 1469-0691.2005.01252.x. (Pubitemid 41535926)
6. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 2007; 13:354-62; PMID:17359318; http://dx.doi.org/10.1111/j.1469-0691.2006.01621.x. (Pubitemid 46390220)
7. Ahmad TA, El-Sayed LH, Haroun M, Hussein AA, El Ashry SH. Development of immunization trials against Klebsiella pneumoniae.vaccine 2012; 30:2411-20; PMID:22100884; http://dx.doi.org/10.1016/j.vaccine. 2011.11.027.
8. Campbell WN, Hendrix E, Cryz S Jr., Cross AS. Immunogenicity of a 24-valent Klebsiella capsular polysaccharidevaccine and an eight-valent Pseudomonas O-polysaccharide conjugatevaccine administered to victims of acute trauma. Clin Infect Dis 1996; 23:179-81; PMID:8816151; http://dx.doi.org/10. 1093/clinids/23.1.179. (Pubitemid 26323817)
9. Chhibber S, Bajaj J. Polysaccharide-iron-regulated cell surface protein conjugatevaccine: its role in protection against Klebsiella pneumoniae-induced lobar pneumonia.vaccine 1995; 13:179-84; PMID:7625113; http://dx.doi.org/10. 1016/0264-410X(95)93133-T.
10. Edelman R, Taylor DN, Wasserman SS, McClain JB, Cross AS, Sadoff JC, et al. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharidevaccine and an eightvalent Pseudomonas O-polysaccharide conjugatevaccine administered simultaneously.vaccine 1994; 12:1288-94; PMID:7856293; http://dx.doi.org/10. 1016/S0264-410X(94)80054-4.
11. Cryz SJ Jr., Mortimer PM, Mansfield V, Germanier R. Seroepidemiology of Klebsiella bacteremic isolates and implications forvaccine development. J Clin Microbiol 1986; 23:687-90; PMID:3517058. (Pubitemid 16136775)
12. Yadav V, Sharma S, Harjai K, Mohan H, Chhibber S. Lipopolysaccharide- mediated protection against Klebsiella pneumoniae-induced lobar pneumonia: intranasal vs. intramuscular route of immunization. Folia Microbiol (Praha) 2005; 50:83-6; PMID:15954538; http://dx.doi.org/10.1007/BF02931298. (Pubitemid 40722167)
13. Cryz SJ Jr., Fürer E, Germanier R. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharidevaccine in humans. J Infect Dis 1985; 151:665-71; PMID:3882856; http://dx.doi.org/10.1093/infdis/151.4.665. (Pubitemid 15102164)
14. Cryz SJ Jr., Mortimer P, Cross AS, Fürer E, Germanier R. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharidevaccine in humans.vaccine 1986; 4:15-20; PMID:3962447; http://dx.doi.org/10.1016/0264- 410X(86)90092-7. (Pubitemid 16129408)
15. Cryz SJ Jr., Mortimer P, Cross AS, Fürer E, Germanier R. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharidevaccine in humans.vaccine 1986; 4:15-20; PMID:3962447; http://dx.doi.org/10.1016/0264- 410X(86)90092-7. (Pubitemid 16129408)
16. Kurupati P, Teh BK, Kumarasinghe G, Poh CL. Identification ofvaccine candidate antigens of an ESBL producing Klebsiella pneumoniae clinical strain by immunoproteome analysis. Proteomics 2006; 6:836-44; PMID:16372264; http://dx.doi.org/10.1002/pmic.200500214. (Pubitemid 43260209)
17. Kurupati P, Ramachandran NP, Poh CL. Protective efficacy of DNAvaccines encoding outer membrane protein A and OmpK36 of Klebsiella pneumoniae in mice. Clinvaccine Immunol 2011; 18:82-8; PMID:21048001; http://dx.doi.org/10.1128/CVI. 00275-10.
18. Etz H, Minh DB, Henics T, Dryla A, Winkler B, Triska C, et al. Identification of in vivo expressedvaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci U S A 2002; 99:6573-8; PMID:11997460; http://dx.doi.org/10.1073/pnas.092569199. (Pubitemid 34526174)
19. Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, et al. Discovery of a novel class of highly conservedvaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008; 205:117-31; PMID:18166586; http://dx.doi.org/10.1084/jem.20071168.
20. Henics T, Winkler B, Pfeifer U, Gill SR, Buschle M, von Gabain A, et al. Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens. Biotechniques 2003; 35:196-202, 204, 206 passim; PMID:12866421.
21. Meinke A, Henics T, Hanner M, Minh DB, Nagy E. Antigenome technology: a novel approach for the selection of bacterialvaccine candidate antigens.vaccine 2005; 23:2035-41; PMID:15755567; http://dx.doi.org/10.1016/j.vaccine.2005.01. 005. (Pubitemid 40341423)
22. www. ecdc.europa.eu/en/publications/Publications/120215-SUR-HAI-2007.pdf
23. Lavender H, Jagnow JJ, Clegg S. Klebsiella pneumoniae type 3 fimbria-mediated immunity to infection in the murine model of respiratory disease. Int J Med Microbiol 2005; 295:153-9; PMID:16047414; http://dx.doi.org/10.1016/j.ijmm.2005.04.001.
24. Regué M, Hita B, Piqué N, Izquierdo L, Merino S, Fresno S, et al. A gene, uge, is essential for Klebsiella pneumoniae virulence. Infect Immun 2004; 72:54-61; PMID:14688080; http://dx.doi.org/10.1128/IAI.72.1.54-61. 2004.
25. Kuenen JD, van Dijke EE, Hol C, Bootsma HJ, Verhoef J, van Dijk H. Protective effects of orally administered, Klebsiella-containing bacterial lysates in mice. FEMS Immunol Med Microbiol 1994; 8:69-75; PMID:8156053; http://dx.doi.org/10.1111/j.1574-695X.1994.tb00427.x.
26. Tomás JM, Benedí VJ, Ciurana B, Jofre J. Role of capsule and O antigen in resistance of Klebsiella pneumoniae to serum bactericidal activity. Infect Immun 1986; 54:85-9; PMID:3531020.
27. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al.; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011; PMID:18947320; http://dx.doi.org/10.1086/591861.
28. Ullmann U. [Bacterial infection agents in hospitalized patients]. Zentralbl Bakteriol Mikrobiol Hyg B 1986; 183:103-13; PMID:3107262.
29. Ortega M, Marco F, Soriano A, Almela M, Martínez JA, López J, et al. Epidemiology and prognostic determinants of bacteraemic biliary tract infection. J Antimicrob Chemother 2012; 67:1508-13; PMID:22408140; http://dx.doi.org/10.1093/jac/dks062.
30. Hansen DS, Mestre F, Alberti S, Hernández-Allés S, Alvarez D, Doménech-Sánchez A, et al. Klebsiella pneumoniae lipopolysaccharide O typing: revision of prototype strains and O-group distribution among clinical isolates from different sources and countries. J Clin Microbiol 1999; 37:56-62; PMID:9854064.
31. Tomas JM, Camprubi S, Williams P. Surface exposure of the O-antigen in Klebsiella pneumoniae O1:K1 serotype strains. Microb Pathog 1988; 5:141-7; PMID:3070259; http://dx.doi.org/10.1016/0882-4010(88)90016-2.
32. Rukavina T, Tícac B, Susa M, Jendrike N, Jonjíc S, Lucin P, et al. Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. Infect Immun 1997; 65:1754-60; PMID:9125558. (Pubitemid 27193597)
33. Mandine E, Salles MF, Zalisz R, Guenounou M, Smets P. Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae. Infect Immun 1990; 58:2828-33; PMID:1696932. (Pubitemid 20267667)
34. Goetsch L, Gonzalez A, Plotnicky-Gilquin H, Haeuw JF, Aubry JP, Beck A, et al. Targeting of nasal mucosaassociated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun 2001; 69:6434-44; PMID:11553588; http://dx.doi.org/10.1128/IAI.69.10.6434-6444. 2001. (Pubitemid 32885209)
35. Struve C, Bojer M, Krogfelt KA. Identification of a conserved chromosomal region encoding Klebsiella pneumoniae type 1 and type 3 fimbriae and assessment of the role of fimbriae in pathogenicity. Infect Immun 2009; 77:5016-24; PMID:19703972; http://dx.doi.org/10.1128/IAI.00585-09.
36. Struve C, Bojer M, Krogfelt KA. Characterization of Klebsiella pneumoniae type 1 fimbriae by detection of phase variation during colonization and infection and impact on virulence. Infect Immun 2008; 76:4055-65; PMID:18559432; http://dx.doi.org/10.1128/IAI.00494-08.
37. Klipstein FA, Engert RF, Houghten RA. Immunological properties of purified Klebsiella pneumoniae heatstable enterotoxin. Infect Immun 1983; 42:838-41; PMID:6358035. (Pubitemid 14230289)
38. Struve C, Forestier C, Krogfelt KA. Application of a novel multi-screening signature-tagged mutagenesis assay for identification of Klebsiella pneumoniae genes essential in colonization and infection. Microbiology 2003; 149:167-76; PMID:12576590; http://dx.doi.org/10.1099/mic.0. 25833-0.
39. Lai YC, Peng HL, Chang HY. Identification of genes induced in vivo during Klebsiella pneumoniae CG43 infection. Infect Immun 2001; 69:7140-5; PMID:11598090; http://dx.doi.org/10.1128/IAI.69.11.7140-7145.2001.
40. Meinke A, Storm M, Henics T, Gelbmann D, Prustomersky S, Kovács Z, et al. Composition of the ANTIGENome of Helicobacter pylori defined by human serum antibodies.vaccine 2009; 27:3251-9; PMID:19200834; http://dx.doi.org/10. 1016/j.vaccine. 2009.01.066.
41. Roe EA, Jones RJ, Dyster RE. Passive immunization of mice against Klebsiella aerogenes. Br J Exp Pathol 1986; 67:25-32; PMID:3511939.
42. Rukavina T, Ticac B, Vasiljev V. IL-10 in antilipopolysaccharide immunity against systemic Klebsiella infections. Mediators Inflamm 2006; 2006:69431; PMID:17392590; http://dx.doi.org/10.1155/MI/2006/69431.
43. Zisman DA, Strieter RM, Kunkel SL, Tsai WC, Wilkowski JM, Bucknell KA, et al. Ethanol feeding impairs innate immunity and alters the expression of Th1-and Th2-phenotype cytokines in murine Klebsiella pneumonia. Alcohol Clin Exp Res 1998; 22:621-7; PMID:9622442; http://dx.doi.org/10.1111/j.1530-0277.1998. tb04303.x.
44. Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009; 126:177-85; PMID:19125888; http://dx.doi.org/10.1111/j.1365-2567.2008.03017.x.
45. Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun 2010; 78:32-8; PMID:19901061; http://dx.doi.org/10.1128/IAI.00929- 09.